Merck fights back against Roche in adjuvant lung cancer therapy

Merck fights back against Roche in adjuvant lung cancer therapy

Source: 
Pharmaforum
snippet: 

Merck & Co’s Keytruda is poised to move even earlier in the treatment of patients with non-small cell lung cancer (NSCLC) after showing efficacy when used to prevent the cancer returning after surgery to remove it in a phase 3 trial.